Lumida
/KRRO
⌘K
Korro Bio Inc

Korro Bio Inc

KRRO
$13.81USD↑+5.74%+0.75 today

MARKET CAP

203.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$13 – $14

52W RANGE

$5
$56

AI Summary

Stalk
Buy NowMedium

KRRO has carved a Stage 1 base after a steep capitulation, enabling mean-reversion entries. The medium-term bias is bullish under mean-reversion eligibility and defined support. Recently, price has held a pullback into the rising 9/21/50-day EMA zone and prior consolidation highs, showing no short-term exhaustion. This presents a favorable entry on a supportive interaction. A breakdown below the EMA confluence and base support would invalidate this bullish posture.

  • ↑HC Wainwright reiterates Buy rating with $15 price target.
  • ↑CoinCodex projects 27.6% upside to $16.46 by end-2026.
  • ↓Profitability metrics remain weak, reflecting poor return generation.
Full analysis →

Buying

4

institutions

Selling

3

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BA

Balyasny Asset Management L.P.

Q2 2026

SELL951.78 K12.54 M+-88.27 K+6.5%0.02%
BI

Blackrock, Inc.

Q2 2026

BUY817.62 K10.78 M+357.62 K+107.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY298.97 K3.94 M+31.22 K+30.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY124.73 K1.65 M+56.23 K+133.7%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL123.79 K1.63 M+-145.32 K-46.4%0.00%
MM

Millennium Management LLC

Q2 2026

BUY118.43 K1.56 M+54.83 K+116.8%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL110.52 K1.46 M+-25.70 K-5.5%0.00%